About OncoCyte (NYSEAMERICAN:OCX)
OncoCyte Corporation focuses on the discovery, development, and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using proprietary sets of genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer. The company was founded in 2009 and is based in Alameda, California. OncoCyte Corporation is a subsidiary of BioTime, Inc.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNYSEAMERICAN:OCX
CUSIPN/A
Phone+1-510-7750515
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on Equity-404.76%
Return on Assets-209.93%
Miscellaneous
EmployeesN/A
Outstanding Shares31,470,000
OncoCyte (NYSEAMERICAN:OCX) Frequently Asked Questions
What is OncoCyte's stock symbol?
OncoCyte trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "OCX."
How were OncoCyte's earnings last quarter?
OncoCyte (NYSEAMERICAN:OCX) issued its earnings results on Monday, April, 2nd. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.13) by $0.00. View OncoCyte's Earnings History.
When is OncoCyte's next earnings date?
What price target have analysts set for OCX?
2 brokers have issued 12-month price objectives for OncoCyte's shares. Their predictions range from $7.75 to $7.75. On average, they expect OncoCyte's share price to reach $7.75 in the next twelve months. View Analyst Ratings for OncoCyte.
Are investors shorting OncoCyte?
OncoCyte saw a increase in short interest during the month of March. As of March 29th, there was short interest totalling 854,481 shares, an increase of 5.9% from the March 15th total of 807,018 shares. Based on an average trading volume of 251,899 shares, the short-interest ratio is currently 3.4 days. Approximately 10.2% of the shares of the stock are sold short.
Who are some of OncoCyte's key competitors?
Some companies that are related to OncoCyte include Delta Apparel (DLA), Condor Hospitality Trust (CDOR), Energy Fuels (UUUU), Nobilis Health (HLTH), Alio Gold (ALO), Pfenex (PFNX), U.S. Geothermal (HTM), Asterias Biotherapeutics (AST), Orchids Paper Products (TIS), inTest (INTT), Matinas BioPharma (MTNB), Ur-energy (URG), Contango Oil & Gas (MCF), Unique Fabricating (UFAB), Transatlantic Petroleum (TAT), Bovie Medical (BVX), CPI Aerostructures (CVU) and Vista Gold (VGZ).
Who are OncoCyte's key executives?
OncoCyte's management team includes the folowing people:
- Mr. William Annett MBA, Pres, Chief Exec. Officer & Director (Age 64)
- Dr. Kristine C. Mechem Ph.D., VP of Marketing & Planninng
- Dr. Lyndal K. Hesterberg Ph.D., Sr. VP of R&D
- Mr. Mitchell S. Levine, Chief Financial Officer
- Mr. Michael G. Vicari, VP of Sales
Has OncoCyte been receiving favorable news coverage?
Press coverage about OCX stock has trended positive this week, according to Accern. The research firm identifies positive and negative news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. OncoCyte earned a coverage optimism score of 0.25 on Accern's scale. They also assigned media coverage about the biotechnology company an impact score of 47.45 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term.
How do I buy shares of OncoCyte?
Shares of OCX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is OncoCyte's stock price today?
One share of OCX stock can currently be purchased for approximately $2.45.
How big of a company is OncoCyte?
OncoCyte has a market capitalization of $67.57 million.
How can I contact OncoCyte?
OncoCyte's mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company can be reached via phone at +1-510-7750515.
MarketBeat Community Rating for OncoCyte (OCX)
MarketBeat's community ratings are surveys of what our community members think about OncoCyte and other stocks. Vote "Outperform" if you believe OCX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OCX will underperform the S&P 500 over the long term. You may vote once every thirty days.
OncoCyte (NYSEAMERICAN:OCX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
2 Wall Street analysts have issued ratings and price targets for OncoCyte in the last 12 months. Their average twelve-month price target is $7.75, suggesting that the stock has a possible upside of 216.33%. The high price target for OCX is $7.75 and the low price target for OCX is $7.75. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.50 | 2.50 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $7.75 | $7.75 | $7.75 | $7.75 |
| Price Target Upside: | 216.33% upside | 252.27% upside | 5.44% upside | 5.44% upside |
OncoCyte (NYSEAMERICAN:OCX) Consensus Price Target History
OncoCyte (NYSEAMERICAN:OCX) Analyst Ratings History
Show:
(Data available from 4/22/2016 forward)
OncoCyte (NYSEAMERICAN:OCX) Earnings History and Estimates Chart
OncoCyte (NYSEAMERICAN OCX) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 4/27/2018 | | | | | | | | |
| 4/2/2018 | Q4 2017 | ($0.1320) | ($0.13) | | | View | Listen |  |
| 11/14/2017 | Q3 2017 | ($0.13) | ($0.12) | | | View | N/A | |
| 8/14/2017 | Q2 2017 | ($0.12) | ($0.13) | | | View | N/A | |
| 4/28/2017 | Q1 2017 | ($0.13) | ($0.16) | | | View | N/A | |
| 2/27/2017 | Q4 2016 | ($0.11) | ($0.11) | | | View | N/A | |
| 11/10/2016 | Q3 2016 | ($0.10) | ($0.10) | | | View | N/A | |
| 8/11/2016 | Q2 2016 | ($0.11) | ($0.10) | | | View | N/A | |
| 5/16/2016 | Q1 2016 | ($0.11) | ($0.12) | | | View | N/A | |
| 3/30/2016 | | ($0.09) | ($0.14) | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
OncoCyte (NYSEAMERICAN:OCX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
OncoCyte (NYSEAMERICAN OCX) Insider Trading and Institutional Ownership History
OncoCyte (NYSEAMERICAN OCX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/28/2018 | Broadwood Partners, L.P. | Major Shareholder | Buy | 3,968,254 | $1.26 | $5,000,000.04 | | |
(Data available from 1/1/2013 forward)
OncoCyte (NYSEAMERICAN OCX) News Headlines
| Source: |
|
OncoCyte (NYSEAMERICAN:OCX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
OncoCyte (NYSEAMERICAN:OCX) Income Statement, Balance Sheet and Cash Flow Statement
OncoCyte (NYSEAMERICAN OCX) Stock Chart for Sunday, April, 22, 2018
Loading chart…
